BACKGROUND: The effect of nucleos(t)ide analogues therapy in patients with decompensated cirrhosis remains unclear. AIM: The purpose of this study was to evaluate the effect of nucleos(t)ide analogues on decompensated cirrhotic patients. METHODS: An online search within PubMed, Web of Science, Embase, Cochrane Central of Register of Controlled Trials and China Biology Medicine disc from 1998-01-01 to 2011-09-05 was conducted. A meta-analysis was performed. Relative risks of mortality rate, Child-Pugh-Turcotte score and hepatitis B e-antigen (HBeAg) seroconversion of the decompensated patients were studied. RESULTS: Eight studies involving 511 patients were included. Data showed that lamivudine and telbivudine significantly decreased the mortality rate (relative risk 0.36, 95 % confidence interval 0.25-0.54), improved the Child-Pugh-Turcotte scores (mean difference -3.23, 95 % confidence interval -3.98 to -2.48) and promoted HBeAg seroconversion (relative risk 7.48, 95 % confidence interval 2.31-24.20). CONCLUSION: For patients with decompensated cirrhosis, lamivudine and telbivudine significantly decrease the mortality rate and disease severity. Also, they promote their HBeAg seroconversion.
BACKGROUND: The effect of nucleos(t)ide analogues therapy in patients with decompensated cirrhosis remains unclear. AIM: The purpose of this study was to evaluate the effect of nucleos(t)ide analogues on decompensated cirrhotic patients. METHODS: An online search within PubMed, Web of Science, Embase, Cochrane Central of Register of Controlled Trials and China Biology Medicine disc from 1998-01-01 to 2011-09-05 was conducted. A meta-analysis was performed. Relative risks of mortality rate, Child-Pugh-Turcotte score and hepatitis B e-antigen (HBeAg) seroconversion of the decompensated patients were studied. RESULTS: Eight studies involving 511 patients were included. Data showed that lamivudine and telbivudine significantly decreased the mortality rate (relative risk 0.36, 95 % confidence interval 0.25-0.54), improved the Child-Pugh-Turcotte scores (mean difference -3.23, 95 % confidence interval -3.98 to -2.48) and promoted HBeAg seroconversion (relative risk 7.48, 95 % confidence interval 2.31-24.20). CONCLUSION: For patients with decompensated cirrhosis, lamivudine and telbivudine significantly decrease the mortality rate and disease severity. Also, they promote their HBeAg seroconversion.
Authors: Robert J Fontana; Emmet B Keeffe; William Carey; Michael Fried; Rajender Reddy; Kris V Kowdley; Consuelo Soldevila-Pico; Leslie A McClure; Anna S F Lok Journal: Liver Transpl Date: 2002-05 Impact factor: 5.799
Authors: J L Dienstag; E R Schiff; T L Wright; R P Perrillo; H W Hann; Z Goodman; L Crowther; L D Condreay; M Woessner; M Rubin; N A Brown Journal: N Engl J Med Date: 1999-10-21 Impact factor: 91.245
Authors: Hie-Won L Hann; Robert J Fontana; Teresa Wright; Gregory Everson; Alfred Baker; Eugene R Schiff; Carolyn Riely; Gaya Anschuetz; Stephen D Gardner; Nathaniel Brown; Dorothea Griffiths Journal: Liver Transpl Date: 2003-01 Impact factor: 5.799
Authors: C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray Journal: N Engl J Med Date: 1998-07-09 Impact factor: 91.245
Authors: Tae Wook Park; Young Min Park; Si Hyun Bae; Jeong Won Jang; Soon Woo Nam; Jong Young Choi; Seung Kew Yoon; Se Hyun Cho; Jin Mo Yang; Nam Ik Han; Byung Min Ahn; Young Suk Lee; Chang Don Lee; Doo Ho Park Journal: Taehan Kan Hakhoe Chi Date: 2002-12
Authors: G Vourli; G Papatheodoridis; M Raptopoulou; G N Dalekos; A Hounta; G Nikolopoulou; I Zouboulis-Vafeiadis; E Manesis; G Kitis; C Gogos; I Ketikoglou; G Hatzis; T Vasilialdis; S Karatapanis; K Mimidis; C Drakoulis; G Touloumi Journal: Hippokratia Date: 2016 Jul-Sep Impact factor: 0.471